The narrative around GLP-1 medications in the UK has been almost entirely about weight loss. But the biology of these drugs is broader than appetite suppression, and the research is accumulating rapidly across a range of conditions that have nothing directly to do with BMI.
This matters for two practical reasons. First, if you have one of these conditions, it may change the risk-benefit calculation for treatment significantly — including whether you meet licensed criteria at a lower BMI than you'd otherwise expect. Second, if you're already on Mounjaro or Wegovy for weight loss, you may be getting benefits you don't know about.
Why this matters beyond weight
GLP-1 receptors aren't only found in the gut and brain — they're expressed in the heart, liver, kidneys, lungs, and pancreas. The medications work through multiple pathways simultaneously: appetite regulation, gastric emptying, insulin secretion, inflammation reduction, and direct organ-level effects that researchers are still fully characterising.
This means the medications' effects extend well beyond what you see on the scale. Some of these effects are direct — the drug interacting with receptors in a specific organ. Others are secondary — flowing from weight loss and metabolic improvement. Distinguishing between the two matters clinically: Wegovy's cardiovascular benefits, for example, appear to be at least partly independent of weight loss, which is why they translate into a licensed indication even for people who don't lose much weight.
MASH — metabolic dysfunction-associated steatohepatitis
The SYNERGY-NASH phase 2 trial (NEJM, 2024) enrolled 190 patients with biopsy-confirmed MASH and moderate-to-severe liver fibrosis (stage F2–F3). At 52 weeks, 44–62% of tirzepatide patients achieved resolution of MASH without worsening of fibrosis, compared to 10% on placebo — across all three doses tested. Phase 3 trials are ongoing.
The ESSENCE phase 3 trial enrolled 1,197 patients with biopsy-confirmed MASH and published interim results in 2025 showing meaningful histological improvement with semaglutide 2.4mg. Semaglutide was approved specifically for MASH in the United States in 2025. UK licensing is not yet confirmed but is expected to follow as the full trial data matures.
MASH — formerly known as non-alcoholic steatohepatitis (NASH) — is a progressive inflammatory form of fatty liver disease. Without treatment, it can progress to cirrhosis, liver failure, and hepatocellular carcinoma. It affects a significant proportion of people who are overweight or obese, often with no symptoms until advanced stages.
The relevance for people at lower BMI is significant. MASH can occur at BMI levels well below 30 — particularly in people of South Asian descent and those with insulin resistance or type 2 diabetes. If you have known or suspected fatty liver disease (elevated liver enzymes on blood tests, fatty liver on ultrasound), this changes your risk-benefit picture for GLP-1 treatment substantially.
Ask your GP specifically about liver enzymes. ALT and AST are routinely measured in blood tests but rarely flagged unless severely elevated. If your ALT is above the normal range, fatty liver disease is a plausible cause and is worth discussing explicitly in the context of GLP-1 treatment.
Obstructive sleep apnoea
The SURMOUNT-OSA trial found that tirzepatide reduced the apnoea-hypopnoea index (AHI — the standard measure of sleep apnoea severity) by ~55–63% over 52 weeks in patients with moderate-to-severe obstructive sleep apnoea and obesity. Notably, approximately half of tirzepatide patients no longer met criteria for moderate-to-severe sleep apnoea at the end of the trial. The FDA approved tirzepatide specifically for sleep apnoea in 2024. UK licensing for this indication is not yet confirmed.
Sleep apnoea is common — estimated to affect 1.5 million people in the UK, with many undiagnosed. It's closely linked to overweight and obesity, though it occurs across a range of BMI levels. If you have diagnosed or suspected sleep apnoea, it constitutes a weight-related comorbidity that places you within licensed GLP-1 prescribing criteria at BMI 27+.
The mechanism here is partly through weight loss — fat deposits around the airway reduce as body weight falls — but also appears to involve direct effects on upper airway tone that are independent of weight. The trial results were meaningfully better than would be expected from weight loss alone.
If you have diagnosed sleep apnoea — even mild — it is a qualifying comorbidity for GLP-1 treatment at BMI 27+. Mention it explicitly in your consultation. Some prescribers focus on the most clinically prominent conditions; sleep apnoea sometimes gets overlooked.
Cardiovascular risk reduction
The SELECT trial enrolled 17,604 people with established cardiovascular disease and overweight/obesity (BMI 27+) who did not have type 2 diabetes. Over a mean follow-up of 39 months, semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% versus placebo. This effect was seen even in patients who lost minimal weight, suggesting a direct cardiovascular mechanism beyond weight loss. Wegovy is now licensed in the UK for cardiovascular risk reduction in this population.
The SURMOUNT-CVOT trial is the ongoing cardiovascular outcomes trial for tirzepatide. Early data suggests cardiovascular risk reduction comparable to semaglutide, but the full results are not yet published and tirzepatide does not yet have a licensed cardiovascular indication in the UK.
This is the area where Wegovy has the strongest licensed case for people below BMI 30. If you have established cardiovascular disease — previous heart attack, stroke, coronary artery disease, or peripheral arterial disease — and your BMI is 27 or above, you are within Wegovy's licensed criteria for cardiovascular risk reduction. This is entirely separate from the weight loss indication.
A 20% reduction in cardiovascular events is a larger clinical effect than most established cardiovascular medications. For people with established heart disease, this is now one of the strongest indications for Wegovy regardless of BMI.
Polycystic ovary syndrome (PCOS)
Multiple smaller trials and observational studies have shown improvements in PCOS-related outcomes with GLP-1 treatment — including reduced androgen levels, improved menstrual regularity, and better insulin sensitivity. A 2024 meta-analysis found that semaglutide improved menstrual regularity in approximately 60% of women with PCOS across the included studies. This is not a licensed indication, but the evidence base is growing and clinical use is increasing.
PCOS affects approximately 1 in 10 women of reproductive age in the UK. Its core features — insulin resistance, elevated androgens, irregular or absent periods, and difficulty conceiving — are closely linked to the metabolic pathways that GLP-1 medications act on. Many women with PCOS struggle with weight management specifically because of the insulin resistance component, and the medications address this directly rather than just reducing appetite.
PCOS does not currently qualify as a "weight-related comorbidity" in the standard licensed criteria language — the listed conditions focus on cardiovascular and metabolic risk factors rather than reproductive health. However, many prescribers will treat PCOS-related insulin resistance as clinically relevant when assessing suitability, particularly in combination with BMI.
If you have PCOS, make it a central part of your consultation conversation — not a footnote. The insulin resistance and metabolic aspects of PCOS represent a legitimate clinical justification for treatment, and a good prescriber will engage with the full picture rather than just your BMI.
Type 2 diabetes prevention
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in the SURMOUNT-1 trial subgroup with prediabetes. The Diabetes Prevention Program found that 5–7% weight loss (achievable with GLP-1 treatment) reduced progression to type 2 diabetes by 58% in people with impaired glucose tolerance. GLP-1 medications are not licensed for diabetes prevention, but the evidence of effect is strong.
Prediabetes — impaired fasting glucose or impaired glucose tolerance — affects an estimated 7 million people in the UK. Most don't know they have it. It is a strong predictor of type 2 diabetes, cardiovascular disease, and kidney disease. Many people with prediabetes are in the BMI 25–30 range rather than clinically obese.
Prediabetes is not currently listed as a qualifying comorbidity in the standard private prescription criteria for GLP-1 medications. But some prescribers will treat it as one — particularly when combined with other risk factors. If you have prediabetes confirmed on blood tests, this should be front and centre in your consultation.
Kidney disease
The FLOW trial (NEJM, 2024) found that semaglutide reduced the risk of major kidney disease events — including end-stage kidney disease — by 24% in people with type 2 diabetes and chronic kidney disease. The FDA has approved semaglutide for kidney disease in this population. UK licensing is under review. This is a separate population from the weight loss indication and may not apply to most people reading this article.
This indication is most relevant for people with both type 2 diabetes and established chronic kidney disease rather than the broader overweight population. We include it because it illustrates the breadth of where the evidence is heading — these medications are increasingly being understood as metabolic disease treatments rather than weight loss drugs.
What this means practically
If you're reading this as someone at lower BMI who is weighing up whether GLP-1 treatment is appropriate for you, the practical takeaways are:
- Your comorbidities matter as much as your BMI. Sleep apnoea, MASH, cardiovascular disease, prediabetes, and PCOS all represent legitimate clinical reasons to consider treatment — some within licensed criteria, others as valid off-label justification.
- Standard blood tests may reveal relevant findings you're not aware of. Elevated liver enzymes suggest fatty liver; impaired fasting glucose suggests prediabetes; testosterone and hormone levels flag PCOS. Ask for a metabolic panel before or during your consultation, not just a BMI check.
- The cardiovascular indication specifically shifts the calculation. If you have established cardiovascular disease, Wegovy is licensed at BMI 27+ for cardiovascular risk reduction — not as a weight loss medication. This is a meaningfully different clinical context.
- A good prescriber will take the full picture. Your BMI, your metabolic markers, your family history, your specific conditions, and your goals should all be part of the conversation. A provider who assesses you solely on BMI and sends you a prescription is not providing adequate care.
Some providers are more experienced than others in managing complex clinical presentations beyond weight loss. Compare all 42 UK providers on cleardose, including those offering fuller clinical assessment.
Compare providers →